Clifford Law Offices, a long-time sponsor of Cristo Rey St. Martin College Prep in Waukegan, is an Academic Sponsor of its "el-e-vate" fundraising event Oct. 22.
Michael S. Krzak, partner at Clifford Law Offices, has been invited to speak at the American Bar Association (ABA) in Washington, D.C. in a program entitled "Tips from Cockpit to Courtroom."
Kevin P. Durkin, partner at Clifford Law Offices, has been named to the Chicago Police Memorial Foundation Executive Committee.
An Illinois federal judge late Friday (Sept. 16, 2016) granted class certification to plaintiffs representing 4.7 million State Farm policyholders involved in a complex Racketeering Influenced and Corrupt Organizations Act ("RICO") regarding an alleged scheme involving campaign contributions being poured into an Illinois Supreme Court justice's race to influence the reversal of a $1.05 billion decision. If successful, that could result in a more than $7.6 billion payout from State Farm for the class given the interest that has accrued.
In recent years, some women who used talcum powder as part of their daily routine have developed ovarian cancer. Presently, more than 1000 women and surviving family members have filed suit against Johnson & Johnson, the makers of Johnson's Baby Powder and Shower to Shower. In 2016, juries in Missouri ordered Johnson & Johnson to pay $72 million and $55 million respectively in cases involving long-time talc users who developed ovarian cancer.
A new defendant in talcum powder litigation
While Johnson & Johnson is the sole defendant in most cases, another company will be joining Johnson & Johnson as a defendant in some of these cases. In early September, the U.S. subsidiary of Australian mining company Rio Tinto has been named along with Johnson & Johnson in a lawsuit filed in Louisiana. This claim was filed on behalf of four women with ovarian cancer and the surviving family members of a woman who died of the disease. The plaintiffs claim that Luzenac America, Rio Tinto's American subsidiary, mined the talc that led to these women developing ovarian cancer.
No sooner than the CEO of the maker of the EpiPen allergy medication aggressively defends the price of the drug than the company announces that it will have available in just a few weeks a generic version of the drug at half the price.
Consumers lashed out at the makers of the allergy shot EpiPen when company executives announced that the cost of the lifesaving medication jumped to more than $600 for a two-pack or reportedly about a 600 percent increase over the last decade.